Abstract
Sleep disorders may increase neurodegenerative diseases risks and alter gut microbiota composition. Saffron (Crocus sativus) supplementation has been linked to sleep improvements and gut microbiome changes, but its effect on sleep quality through gut microbiota-brain axis modulation remains unexplored. A randomised, placebo-controlled pilot study of saffron (30mg/day for 4-weeks) was conducted with 52 older adults (55-85 years) experiencing sleep complaints. Subjective and objective sleep quality were measured using validated questionnaires and electroencephalography-based sleep tracker respectively. A subgroup (n=26) underwent microbiome analysis. Saffron supplementation improved subjective sleep quality (p=0.02) and sleep efficiency (p=0.04). Objective measures showed reduced latency to persistent sleep (p=0.003) and sleep onset latency (p=0.03). Linear discriminant analysis effect size analysis of the microbiome revealed increases in Faecalibacterium (q=0.013), Lachnoclostridium (q=0.045), Prevotella (q=0.022), UBA1819 (q=0.020) and Oscillibacter (q=0.045), while decreasing Dialister (q=0.028). Univariate analysis further indicated increases in Lachnospiraceae-UGC-001 (p=0.020) and Roseburia (p=0.03), with a decrease in Turicibacter (p=0.045) in the saffron group. Oscillibacter and UBA1819 correlated with subjective measures of sleep efficiency (r=0.63, p=0.0007) and sleep latency (r=-0.39, p=0.04. Changes in Dialister, Turicibacter and UBA1819 were correlated with several measures of objective sleep quality including wake duration, latency to persistent sleep and wake-after-sleep-onset. Four-weeks saffron supplementation improved both subjective and objective sleep quality in older adults with sleep complaints, while increasing gut bacteria that produce short-chain fatty acids. These results pave the way for further randomised controlled trials exploring the links between sleep quality and gut health and may help devising new preventative strategies for age-related brain disorders.
Competing Interest Statement
DV receives funding from Activ Inside. L.P D.G. work for Activ Inside and provided the saffron extract (Safr InsideTM). Activ Inside was not involved in the design, implementation, analysis, and interpretation of the data. All the other authors have no conflict of interest to declare.
Clinical Trial
NCT05315986
Funding Statement
This project was supported by the UK Research & Innovation (UKRI) Healthy Ageing Catalyst Awards (Grant ES/W006367/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The conduct, evaluation and documentation of this study abide with the Good Clinical Practice (GCP) guidelines and the principles of the Declaration of Helsinki. The study protocol was approved by the UEA FMH Ethics Committee (ETH2122-1829). All participants provided signed informed consent prior to participating to the study. The trial was registered at https://clinicaltrials.gov (NCT05315986).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† These authors share senior authorship
Data availability
The 16S rRNA gene sequence data have been deposited in the NCBI BioProject database (https://www.ncbi.nlm.nih.gov/bioproject/) under accession number PRJNA998744 (https://dataview.ncbi.nlm.nih.gov/object/PRJNA998701). Other original data will be made available from the corresponding author on reasonable request.
